Nalaganje...
Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes
Cardiovascular disease is the leading cause of morbidity and mortality among patients with diabetes mellitus, as well as the leading diabetes-associated health care cost. The prevalence and associated impact of cardiovascular disease among those with diabetes engenders the need to identify cardiovas...
Shranjeno v:
| izdano v: | Vasc Health Risk Manag |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6292223/ https://ncbi.nlm.nih.gov/pubmed/30573964 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/VHRM.S168472 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|